肿瘤坏死因子抑制剂诱导的儿童克罗恩病患者银屑病经乌司奴单抗成功治疗。
Tumor Necrosis Factor Inhibitor-Induced Psoriasis in a Pediatric Crohn's Disease Patient Successfully Treated with Ustekinumab.
出版信息
J Drugs Dermatol. 2020 Mar 1;19(3):328-331.
BACKGROUND
Tumor necrosis factor (TNF) inhibitors are widely used in pediatric patients with inflammatory bowel disease, as well as psoriasis. However, there is growing evidence that these medications can also paradoxically induce a psoriasiform skin reaction in a subset of patients.
GOALS
We seek to share our experience in treating severe TNF inhibitor-induced psoriasis in a pediatric patient with Crohn’s disease.
STUDY
We report a case of a 10-year-old female with Crohn’s disease, who developed psoriasis after twelve months of infliximab therapy. Her skin disease was recalcitrant to topical therapies, methotrexate, and phototherapy.
RESULTS
The patient was transitioned to ustekinumab with significant improvement in her symptoms and maintenance of remission of her bowel disease.
CONCLUSION
This is the first reported case of a school-age pediatric patient with TNF inhibitor-induced psoriasis treated with ustekinumab. Controlled trials are warranted to fully assess the safety and efficacy of ustekinumab for treating TNF inhibitor-induced psoriasis in the pediatric population.J Drugs Dermatol. 2020;19(3): doi:10.36849/JDD.2020.2106.
背景
肿瘤坏死因子（TNF）抑制剂广泛用于炎症性肠病和银屑病的儿科患者。然而，越来越多的证据表明，这些药物也会在一部分患者中反常地诱导出银屑病样皮肤反应。
目的
我们旨在分享我们在治疗一名患有克罗恩病的儿科患者严重 TNF 抑制剂诱导性银屑病方面的经验。
研究
我们报告了一例 10 岁女性克罗恩病患者，在使用英夫利昔单抗治疗 12 个月后出现银屑病。她的皮肤疾病对局部治疗、甲氨蝶呤和光疗均无反应。
结果
患者转为使用乌司奴单抗治疗，其症状显著改善，且肠病缓解得以维持。
结论
这是首例报告的 TNF 抑制剂诱导性银屑病的学龄期儿科患者用乌司奴单抗治疗的病例。需要进行对照试验来充分评估乌司奴单抗治疗 TNF 抑制剂诱导性银屑病在儿科人群中的安全性和疗效。J 皮肤病药物学杂志。2020;19(3)：doi:10.36849/JDD.2020.2106.
Zotero 插件